Rein Therapeutics, Inc. Common Stock RNTX Business Segments
| FY'25 | FY'24 | FY'23 | ||
|---|---|---|---|---|
| Cost of Goods Sold by Product | ||||
| License And Maintenance | $35K0.0% | $35K-75.9% | $145K— | |
| License | $25K— | —— | $35K— | |
| Research And Development Expense by Product | ||||
| Clinical Operation Activities | $4.29M+9.5% | $3.91M+408% | $771K— | |
| CMC Activities | $2.24M-49.5% | $4.43M+1,972% | $214K— | |
| Employee Related Expenses | $2.12M-3.7% | $2.2M+81.1% | $1.21M— | |
| Facilities And Other Expenses | $74K+57.4% | $47K0.0% | $47K— | |
| Professional Fees For Services | $44K— | —— | $324K— | |
| General And Administrative Expense by Product | ||||
| Employee Related Expenses | $3.75M-31.4% | $5.47M+101% | $2.72M— | |
| Facilities And Other Expenses | $1.96M-8.3% | $2.14M+35.4% | $1.58M— | |
| Professional Fees For Services | $5.19M-17.0% | $6.26M-11.3% | $7.05M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Rein Therapeutics, Inc. Common Stock break its business down?
- Rein Therapeutics, Inc. Common Stock (RNTX) reports cost of goods sold by product across 2 parts — License And Maintenance and License. Each is extracted from the segment footnotes and tracked over time.
- Where does Rein Therapeutics, Inc. Common Stock's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Rein Therapeutics, Inc. Common Stock's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.